GlassScriptPhysician profile
Sarah F Sabin
NPI 1265435168
$4,113.49
in general payments reported to CMS, 2019-2025
35 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $477 · 2021: $323 · 2022: $797 · 2023: $1,063 · 2024: $492 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.46 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.16 | 2019-2023 | Lo Loestrin Fe |
| Gynesonics, INC. | $583.38 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $574.65 | 2020-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $230.49 | 2019-2025 | Slynd, Solosec |
| Aspira Women'S Health INC | $164.31 | 2023 | Ova1 |
| Minerva Surgical, INC | $151.69 | 2019 | |
| Hologic Sales and Service, LLC | $138.63 | 2022-2025 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $137.80 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $137.16 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $133.29 | 2021-2025 | |
| Amgen INC. | $130.53 | 2019-2023 | Evenity, Prolia |
| Channel Medsystems, INC. | $103.10 | 2023 | |
| Pfizer INC. | $102.21 | 2020-2025 | |
| Boston Scientific Corporation | $93.11 | 2019 | |
| Myriad Women'S Health, INC. | $65.66 | 2023 | Myrisk |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $61.46 | 2022 | |
| Merck Sharp & Dohme LLC | $59.11 | 2019-2020 | |
| Coopersurgical, INC. | $57.72 | 2019-2023 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $55.91 | 2019-2023 | |
| Smith+Nephew, INC. | $49.80 | 2023-2025 | Stravix, Pico 14 |
| Organon LLC | $49.66 | 2022-2024 | Nexplanon |
| Sage Therapeutics, LLC | $44.06 | 2022-2025 | Zurzuvae |
| Millicent US INC | $43.39 | 2025 | Femlyv |
| Agile Therapeutics, INC. | $43.38 | 2022-2023 | Twirla |
| Daiichi Sankyo INC. | $38.06 | 2019-2022 | |
| Lupin INC. | $35.90 | 2019-2020 | |
| Evofem Biosciences, INC. | $35.53 | 2021 | |
| Myovant Sciences INC. | $35.31 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $29.27 | 2019 | |
| Sanofi Pasteur INC. | $20.07 | 2024 | |
| Roche Diagnostics Corporation | $17.35 | 2019 | |
| Dysis Medical, INC. | $14.71 | 2022 | |
| Convatec INC. | $14.27 | 2022 | |
| Medline Industries LP | $13.86 | 2023 | Medline Industries, INC., Z-Guard |
| Ascend Therapeutics US, LLC | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Sabin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.